ES2528348T3 - Preparación farmacéutica para el tratamiento de la hiperplasia prostática benigna - Google Patents

Preparación farmacéutica para el tratamiento de la hiperplasia prostática benigna Download PDF

Info

Publication number
ES2528348T3
ES2528348T3 ES12192951.7T ES12192951T ES2528348T3 ES 2528348 T3 ES2528348 T3 ES 2528348T3 ES 12192951 T ES12192951 T ES 12192951T ES 2528348 T3 ES2528348 T3 ES 2528348T3
Authority
ES
Spain
Prior art keywords
treatment
pharmaceutical preparation
benign prostatic
bromelain
prostatic hyperplasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12192951.7T
Other languages
English (en)
Inventor
Lucia Desser
Bernhard Lotz
Thomas Mohr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volopharm GmbH
Original Assignee
Volopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volopharm GmbH filed Critical Volopharm GmbH
Application granted granted Critical
Publication of ES2528348T3 publication Critical patent/ES2528348T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Preparación farmacéutica que comprende al menos dos proteasas para su uso en el tratamiento de la hipertrofia/hiperplasia prostática benigna, en la que la preparación es administrada por vía oral y las al menos dos proteasas son seleccionadas del grupo que consiste en bromelaína, papaína y ficina.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
E12192951
20-01-2015
Tabla 2: Inhibición de la formación de tubo en % en HUVEC en presencia de VEGF. Los resultados se muestran como % de inhibición de la formación de tubo, siendo 0 % la formación de tubo en las muestras tratadas sólo con VEGF.
Bromelaína
Natoquinasa Papaína % inhibición de la formación de tubo
75,00 %
25,00 % 0,00 % 98,11 %
16,67 %
16,67 %
66,67 % 93,52 %
25,00 %
25,00 %
50,00 % 87,75 %
0,00 %
75,00 % 25,00 % 87,42 %
75,00 %
0,00 % 25,00 % 86,34 %
25,00 %
0,00 % 75,00 % 83,77 %
16,67 %
66,67 % 16,67 % 83,65 %
50,00 %
0,00 % 50,00 % 82,73 %
0,00 %
50,00 % 50,00 % 80,01 %
0,00 %
25,00 % 75,00 % 78,26 %
33,33 %
33,33 %
33,33 %
74,14 %
25,00 %
75,00 % 0,00 % 61,57 %
50,00 %
25,00 % 25,00 % 47,78 %
0,00 %
0,00 %
100,00 % 39,86 %
5 La Tabla 2 muestra las longitudes de tubo expresadas como % de inhibición de la formación de tubo. Los resultados indican claramente que:
1.
La formación del tubo es inhibida por mezclas de bromelaína, natoquinasa y papaína;
2.
La combinación de bromelaína, natoquinasa y papaína tiene un efecto mayor que los fármacos solos.
La Figura 3(a) muestra la combinación bromelaína 25 %, natoquinasa 50 % y papaína 25 %. (B) muestra el control
10 tratado con VEGF. Mientras que en el control de VEGF es visible un patrón estrecho de tubos formados (flechas), la muestra tratada con enzima muestra amplias áreas sin formación de tubo que indican actividad antiangiogénica del cóctel de enzimas.
Ejemplo 3:
La influencia de preparaciones que comprenden bromelaína en combinación con otras enzimas sobre las células
15 endoteliales de próstata humana (HProsEC) se ha analizado de forma análoga al ejemplo 2, con modificaciones menores. Brevemente, las células se privaron de nutrientes durante 24 horas en medio basal endotelial-2 (MV) (Lonza, Verviers) suplementado con ácido ascórbico e hidrocortisona. Las células se sembraron a una densidad de
10.000 por pocillo en microplacas de titulación de 96 pocillos recubiertas con Matrigel y se incubaron en ausencia o presencia de 5 ng de VEGF/ml con combinaciones de enzimas (bromelaína 100 % o enzima 50 % y bromelaína 20 50 % a 12,5 μg/ml total). Después de 6 horas, los tubos se fotografiaron y se midieron usando el software ImageJ (Instituto Nacional de Salud, Bethesda, EE.UU.). Se han obtenido los siguientes resultados: enzima + bromelaína % inhibición del tubo Formación gen enzima 25 % Inhibición de formación de tubos
enzima + bromelaína Brinasa 21,00 % 81,00 %
11
imagen10
imagen11

Claims (1)

  1. imagen1
ES12192951.7T 2007-12-03 2008-12-03 Preparación farmacéutica para el tratamiento de la hiperplasia prostática benigna Active ES2528348T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0196207A AT506095A1 (de) 2007-12-03 2007-12-03 Verwendung von proteasen
AT19622007 2007-12-03

Publications (1)

Publication Number Publication Date
ES2528348T3 true ES2528348T3 (es) 2015-02-09

Family

ID=40404976

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12192951.7T Active ES2528348T3 (es) 2007-12-03 2008-12-03 Preparación farmacéutica para el tratamiento de la hiperplasia prostática benigna

Country Status (11)

Country Link
US (1) US8231870B2 (es)
EP (2) EP2224948A1 (es)
JP (1) JP2011505385A (es)
AT (1) AT506095A1 (es)
CA (1) CA2705986C (es)
DK (1) DK2559439T3 (es)
ES (1) ES2528348T3 (es)
MX (1) MX2010005629A (es)
PL (1) PL2559439T3 (es)
RU (1) RU2485971C2 (es)
WO (1) WO2009070818A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI482629B (zh) * 2008-07-01 2015-05-01 Tobishi Pharmaceutical Co 下泌尿道疾病治療劑及下泌尿道症狀改善劑
WO2010029453A1 (en) * 2008-09-10 2010-03-18 Pt.Dexa Medica Composition of thrombolytic agent and anti thrombosis and also its production method
ES2647566T3 (es) * 2011-01-31 2017-12-22 Lucolas-M.D. Ltd. Combinaciones de inhibidores de aromatasa y antioxidantes
AU2012253379A1 (en) 2011-05-12 2013-11-21 Healthpoint, Ltd. Wound debridement compositions containing seaprose and methods of wound treatment using same
AU2013259360B2 (en) * 2012-05-11 2017-07-13 Smith & Nephew, Inc. Use of Seaprose to remove bacterial biofilm
ITMI20121997A1 (it) * 2012-11-23 2014-05-24 Velleja Res Srl Composizioni fibrinolitiche per la prevenzione e il trattamento degli stati flebotrombotici
US10086053B2 (en) 2012-12-06 2018-10-02 Giuseppe CARPIGNOLI Therapeutic vegetable substances
ITTO20121050A1 (it) * 2012-12-06 2014-06-07 Giuseppe Carpignoli Sostanze vegetali ad effetto curativo
CN110755599A (zh) * 2013-10-23 2020-02-07 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása
WO2016032944A1 (en) * 2014-08-25 2016-03-03 Anatara Lifesciences Limited Anti-diarrhea formulation which avoids antimicrobial resistance
AU2017304271A1 (en) 2016-07-27 2019-02-28 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
IT201600081379A1 (it) * 2016-08-03 2018-02-03 Neilos S R L Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
US11413300B2 (en) 2017-01-30 2022-08-16 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
JP7207877B2 (ja) * 2018-06-27 2023-01-18 小林製薬株式会社 ナットウキナーゼを含む食品
JP7207878B2 (ja) * 2018-06-27 2023-01-18 小林製薬株式会社 ナットウキナーゼを含む食品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5045690A (en) 1989-01-27 1990-08-24 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
JPH05229983A (ja) * 1992-02-21 1993-09-07 Sankyo Co Ltd レトロジヒドロカルコン化合物
DE4305460C2 (de) 1993-02-23 1997-09-04 Albert Dr Scheller Pharmazeutische oder kosmetische, Enzyme enthaltende Zubereitung, Verfahren zu deren Herstellung und deren Verwendung
JP3978250B2 (ja) * 1996-08-16 2007-09-19 株式会社フジモト・コーポレーション テストステロン５α−リダクターゼ阻害剤
US20010025059A1 (en) * 2000-01-10 2001-09-27 Kastke Floyd A. Composition and method for treating non-bacterial prostatitis
ZA200002342B (en) 2000-05-12 2001-01-11 Pharmachoice Healthcare Propri Nutritional supplement.
EP1443954B1 (en) 2001-10-26 2010-11-24 The Scripps Research Institute Targeted thrombosis by tissue factor polypeptides
AU2002333006A1 (en) * 2002-09-19 2004-04-08 Gilberto De Nucci Pharmaceutical composition comprising carriers for products
LV13161B (en) * 2004-02-16 2005-07-20 Maris Skromanis Proteolytic pharmaceutical composition
US20060024385A1 (en) 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
US7758594B2 (en) 2005-05-20 2010-07-20 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
RU2306145C1 (ru) * 2006-03-28 2007-09-20 Олег Викторович Бейдик Средство для лечения хронического простатита

Also Published As

Publication number Publication date
PL2559439T3 (pl) 2015-04-30
RU2485971C2 (ru) 2013-06-27
CA2705986A1 (en) 2009-06-11
DK2559439T3 (en) 2014-12-08
MX2010005629A (es) 2010-08-18
US20100254968A1 (en) 2010-10-07
RU2010127336A (ru) 2012-01-10
EP2559439B1 (en) 2014-11-26
EP2224948A1 (en) 2010-09-08
AT506095A1 (de) 2009-06-15
US8231870B2 (en) 2012-07-31
WO2009070818A1 (en) 2009-06-11
CA2705986C (en) 2017-06-13
JP2011505385A (ja) 2011-02-24
EP2559439A1 (en) 2013-02-20

Similar Documents

Publication Publication Date Title
ES2528348T3 (es) Preparación farmacéutica para el tratamiento de la hiperplasia prostática benigna
Schmitt et al. COVID-19 and cellular senescence
Xu et al. HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9
Donadelli et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine
Coiras et al. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs
Chaudhuri et al. Poly (ADP-ribosyl) glycohydrolase prevents the accumulation of unusual replication structures during unperturbed S phase
Hsin et al. N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells
Agustini et al. Cardioprotection mechanism of mangiferin on doxorubicin-induced rats: Focus on intracellular calcium regulation
Garcia et al. The development of anti-inflammatory drugs for infectious diseases
DK1649017T4 (da) Anvendelse af RNA i inhiberende PARP aktivitet til fremstillingen af et lægemiddel til behandlingen af cancer
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
Malami et al. Crude extracts, flavokawain B and alpinetin compounds from the rhizome of alpinia mutica induce cell death via UCK2 enzyme inhibition and in turn reduce 18S rRNA biosynthesis in HT-29 cells
Hwang et al. BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens
Sanna et al. Dual HIV-1 reverse transcriptase and integrase inhibitors from Limonium morisianum Arrigoni, an endemic species of Sardinia (Italy)
Wang et al. Histone acetylation plays an important role in MC-LR-induced apoptosis and cycle disorder in SD rat testicular cells
Chen et al. Power and promise of ubiquitin carboxyl-terminal hydrolase 37 as a target of cancer therapy
Tsuchiya et al. Intracellularly transported adenosine induces MCF-7 human breast cancer cells by accumulating AMID in the nucleus
Ji et al. Inhibition of invasion and metastasis of human liver cancer HCCLM3 cells by portulacerebroside A
Zhang et al. MicroRNA-24-3p alleviates cardiac fibrosis by suppressing cardiac fibroblasts mitophagy via downregulating PHB2
Zhao et al. Gene expression profiling identifies the novel role of immunoproteasome in doxorubicin-induced cardiotoxicity
DE60234329D1 (de) Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2
Chen et al. Lucidone suppresses dengue viral replication through the induction of heme oxygenase-1
Sanchez-Velazquez et al. Generation of a reporter yellow fever virus for high throughput antiviral assays
Hsieh et al. Differential endoplasmic reticulum stress signaling pathways mediated by iNOS
Farooqi et al. Androgen receptor and gene network: micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells